A Prospective, Open-Label, Flexible-Dose Study of Quetiapine in the Treatment of Delirium
J Clin Psychiatry 2003;64(11):1316-1321
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Delirium is an organic psychiatric
syndrome characterized by fluctuating consciousness and impaired
cognitive functioning. High-potency typical neuroleptics have
traditionally been used as first-line drugs in the treatment of
delirium. However, these drugs are frequently associated with
undesirable adverse events including extrapyramidal symptoms
(EPS). The purpose of the present open-label, flexible-dose study
was to provide preliminary data on the usefulness and safety of
quetiapine for patients with delirium.
Method: Twelve patients with DSM-IV delirium
were treated with flexible doses of open-label quetiapine (mean
± SD dosage = 44.9 ± 31.0 mg/day). To evaluate the usefulness
and safety of quetiapine, scores from the Delirium Rating Scale,
Japanese version, were assessed every day (for 1 outpatient, at
least twice per week), and scores from the Mini-Mental State
Examination, Japanese version, and the Drug-Induced
Extrapyramidal Symptom Scale were assessed at baseline and after
remission of delirium. Data were gathered from April to October
Results: All patients achieved remission of
delirium several days after starting quetiapine (mean ± SD
duration until remission = 4.8 ± 3.5 days). Quetiapine treatment
was well tolerated, and no clinically relevant change in EPS was
Conclusion: Quetiapine may be a useful
alternative to conventional neuroleptics in the treatment of
delirium due to its rapid onset and relative lack of adverse
events. Further double-blind, placebo-controlled studies are